{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:12:51Z","timestamp":1789665171838,"version":"4.0.1"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00040","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T05:46:42Z","timestamp":1580190402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D"],"prefix":"10.3389","volume":"11","author":[{"given":"Ece Canan","family":"Sayitoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Georgoudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chrobok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Ozkazanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Josey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara M.","family":"Chinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Potens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevriye","family":"Pamukcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Mardinoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren","family":"Alici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry Thomas","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Sutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil Doganay","family":"Duru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrc3087","article-title":"Advances in sarcoma genomics and new therapeutic targets","volume":"11","author":"Taylor","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12916-017-0872-y","article-title":"Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new","volume":"15","author":"Frezza","year":"2017","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/cncr.31176","article-title":"Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral\/soft tissue sarcoma managed in reference centers","volume":"124","author":"Penel","year":"2018","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1001\/jama.285.13.1736","article-title":"Association of cancer with AIDS-related immunosuppression in adults","volume":"285","author":"Frisch","year":"2001","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"Contribution to the knowledge of sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0163-7258(94)90023-X","article-title":"Coley's toxins, tumor necrosis factor and cancer research: a historical perspective","volume":"64","author":"Wiemann","year":"1994","journal-title":"Pharmacol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"168145","DOI":"10.1155\/2013\/168145","article-title":"A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma","volume":"2013","author":"Maki","year":"2013","journal-title":"Sarcoma"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-3-31","article-title":"Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma","volume":"3","author":"Kawaguchi","year":"2005","journal-title":"J Transl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/j.1349-7006.2012.02370.x","article-title":"SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group","volume":"103","author":"Kawaguchi","year":"2012","journal-title":"Cancer Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/cas.12226","article-title":"Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients","volume":"104","author":"Takahashi","year":"2013","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1089\/1084978042484812","article-title":"Phase I\/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas","volume":"19","author":"Dillman","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/14653249.2011.610303","article-title":"Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor","volume":"14","author":"Montagna","year":"2012","journal-title":"Cytotherapy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1634\/theoncologist.2016-0025","article-title":"Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas","volume":"23","author":"Nathenson","year":"2018","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/icb.2010.78","article-title":"Activating and inhibitory receptors of natural killer cells","volume":"89","author":"Pegram","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/eji.201344272","article-title":"Effect of tumor cells and tumor microenvironment on NK-cell function","volume":"44","author":"Vitale","year":"2014","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.1102267","article-title":"Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44","volume":"187","author":"Rosental","year":"2011","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e59552","DOI":"10.1371\/journal.pone.0059552","article-title":"Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44","volume":"8","author":"Horton","year":"2013","journal-title":"PLoS ONE"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e8254","DOI":"10.1097\/MD.0000000000008254","article-title":"The prognostic value of PCNA expression in patients with osteosarcoma: a meta-analysis of 16 studies","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1333214","DOI":"10.1080\/2162402X.2017.1333214","article-title":"Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis","volume":"6","author":"Kiany","year":"2017","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1084\/jem.20030788","article-title":"Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule","volume":"198","author":"Bottino","year":"2003","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/intimm\/dxh059","article-title":"Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2\/CD112)","volume":"16","author":"Tahara-Hanaoka","year":"2004","journal-title":"Int Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00262-015-1657-9","article-title":"Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells","volume":"64","author":"Boerman","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","article-title":"Toil enables reproducible, open source, big biomedical data analyses","volume":"35","author":"Vivian","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/mt.2008.6","article-title":"A multicolor panel of novel lentiviral \u201cgene ontology\u201d (LeGO) vectors for functional gene analysis","volume":"16","author":"Weber","year":"2008","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1089\/hum.2012.080","article-title":"Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy","volume":"23","author":"Sutlu","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0141074","DOI":"10.1371\/journal.pone.0141074","article-title":"A novel method for assessment of natural killer cell cytotoxicity using image cytometry","volume":"10","author":"Somanchi","year":"2015","journal-title":"PLoS ONE"},{"key":"B32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-3684-7_9","article-title":"Assessment of natural killer cell cytotoxicity using image cytometry method","volume":"1441","author":"McCulley","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1074\/jbc.M109.045906","article-title":"Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands","volume":"285","author":"Fernandez-Messina","year":"2010","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/sj.leu.2404572","article-title":"A redundant oncogenic potential of the retinoic receptor (RAR) alpha, beta and gamma isoforms in acute promyelocytic leukemia","volume":"21","author":"Marinelli","year":"2007","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/0008-5472.CAN-06-3399","article-title":"Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors","volume":"67","author":"Raja Gabaglia","year":"2007","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0211538","DOI":"10.1371\/journal.pone.0211538","article-title":"Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: implications for the metastatic cascade","volume":"14","author":"Cluxton","year":"2019","journal-title":"PLoS ONE"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-08-2502","article-title":"Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases","volume":"15","author":"Carreno","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.4049\/jimmunol.173.11.6767","article-title":"Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo","volume":"173","author":"Kabelitz","year":"2004","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1074\/mcp.R500009-MCP200","article-title":"A human protein atlas for normal and cancer tissues based on antibody proteomics","volume":"4","author":"Uhlen","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"B42","first-page":"68","article-title":"A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood","volume":"2","author":"Klingemann","year":"1996","journal-title":"Biol Blood Marrow Transplant."},{"key":"B43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259) T cells in synovial sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e1250050","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","volume":"6","author":"Kailayangiri","year":"2017","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","article-title":"Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5","volume":"97","author":"Tsukahara","year":"2006","journal-title":"Cancer Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1468-3083.2010.03644.x","article-title":"Human leucocyte antigen class I and class II antigen expression in malignant fibrous histiocytoma, fibrosarcoma and dermatofibrosarcoma protuberans is significantly downregulated","volume":"24","author":"Meissner","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/path.2537","article-title":"Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition","volume":"218","author":"Berghuis","year":"2009","journal-title":"J Pathol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e0013174","DOI":"10.1371\/journal.pone.0013174","article-title":"Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice","volume":"5","author":"Brodin","year":"2010","journal-title":"PLoS ONE"},{"key":"B51","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/imt.09.47","article-title":"Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study","volume":"1","author":"Barkholt","year":"2009","journal-title":"Immunotherapy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2018.04.009","article-title":"NK cells mediate a crucial graft-versus-leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia","volume":"39","author":"Locatelli","year":"2018","journal-title":"Trends Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1586905","DOI":"10.1155\/2018\/1586905","article-title":"High-risk leukemia: past, present, and future role of NK cells","volume":"2018","author":"Mavers","year":"2018","journal-title":"J Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fimmu.2015.00605","article-title":"Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity","volume":"6","author":"Dahlberg","year":"2015","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1177\/1758834017728927","article-title":"Managing sarcoma: where have we come from and where are we going?","volume":"9","author":"Bleloch","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/eji.201948140","article-title":"Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer","volume":"49","author":"Parlar","year":"2019","journal-title":"Eur J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ebiom.2019.01.031","article-title":"NK cells specifically TCR-dressed to kill cancer cells","volume":"40","author":"Mensali","year":"2019","journal-title":"EBioMedicine"},{"key":"B58","first-page":"2241","article-title":"Cancer immunotherapy using NKG2D and DNAM-1 systems","volume":"32","author":"Morisaki","year":"2012","journal-title":"Anticancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tranon.2016.07.003","article-title":"Altered expression of natural cytotoxicity receptors and NKG2D on peripheral blood NK cell subsets in breast cancer patients","volume":"9","author":"Nieto-Velazquez","year":"2016","journal-title":"Transl Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/2326-6066.CIR-18-0022","article-title":"NK cell education in tumor immune surveillance: DNAM-1\/KIR receptor ratios as predictive biomarkers for solid tumor outcome","volume":"6","author":"Guillamon","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.4049\/jimmunol.169.8.4098","article-title":"Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding","volume":"169","author":"Salih","year":"2002","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0152982","DOI":"10.1371\/journal.pone.0152982","article-title":"Increased soluble CD155 in the serum of cancer patients","volume":"11","author":"Iguchi-Manaka","year":"2016","journal-title":"PLoS ONE"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-10-0735","article-title":"Cytotoxicity of activated natural killer cells against pediatric solid tumors","volume":"16","author":"Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1016\/j.molimm.2008.06.016","article-title":"NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways","volume":"45","author":"Verhoeven","year":"2008","journal-title":"Mol Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3892\/ol.2013.1280","article-title":"Prognostic significance of CD155 mRNA expression in soft tissue sarcomas","volume":"5","author":"Atsumi","year":"2013","journal-title":"Oncol Lett"},{"key":"B66","doi-asserted-by":"publisher","first-page":"379568","DOI":"10.1155\/2015\/379568","article-title":"The clinical and pathological significance of nectin-2 and DDX3 expression in pancreatic ductal adenocarcinomas","volume":"2015","author":"Liang","year":"2015","journal-title":"Dis Markers"},{"key":"B67","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1476-4598-12-60","article-title":"Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers","volume":"12","author":"Oshima","year":"2013","journal-title":"Mol Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/cas.13992","article-title":"Nectin-2 in ovarian cancer: how is it expressed and what might be its functional role?","volume":"110","author":"Bekes","year":"2019","journal-title":"Cancer Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood-2004-09-3548","article-title":"Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)","volume":"105","author":"Pende","year":"2005","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12094-015-1348-1","article-title":"Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma","volume":"18","author":"Karabulut","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"B71","first-page":"179","article-title":"Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell\/adenosquamous carcinomas and adenocarcinoma of gallbladder","volume":"6","author":"Miao","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.humpath.2014.06.001","article-title":"Low expression of CD112 is associated with poor overall survival in patients with hepatocellular carcinoma","volume":"45","author":"Huang","year":"2014","journal-title":"Hum Pathol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.3892\/ol.2018.7953","article-title":"Elevated Nectin-2 expression is involved in esophageal squamous cell carcinoma by promoting cell migration and invasion","volume":"15","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"B74","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/bloodadvances.2017015230","article-title":"Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy","volume":"2","author":"Mastaglio","year":"2018","journal-title":"Blood Adv"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e1196308","DOI":"10.1080\/2162402X.2016.1196308","article-title":"Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing","volume":"5","author":"Kearney","year":"2016","journal-title":"Oncoimmunology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","article-title":"CD155T\/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer","volume":"77","author":"He","year":"2017","journal-title":"Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.5858\/arpa.2016-0580-OA","article-title":"Validation of an immunohistochemistry assay for detection of CD155, the poliovirus receptor, in malignant gliomas","volume":"141","author":"Chandramohan","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/jcmm.13301","article-title":"CD155 knockdown promotes apoptosis via AKT\/Bcl-2\/Bax in colon cancer cells","volume":"22","author":"Zheng","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/gut.49.2.236","article-title":"Overexpression of the CD155 gene in human colorectal carcinoma","volume":"49","author":"Masson","year":"2001","journal-title":"Gut"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1349-7006.2010.01530.x","article-title":"Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma","volume":"101","author":"Nakai","year":"2010","journal-title":"Cancer Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"882","DOI":"10.18632\/oncotarget.594","article-title":"Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma","volume":"3","author":"Bevelacqua","year":"2012","journal-title":"Oncotarget"},{"key":"B82","first-page":"2287","article-title":"Clinical significance of CD155 expression in human pancreatic cancer","volume":"35","author":"Nishiwada","year":"2015","journal-title":"Anticancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.4049\/jimmunol.0901226","article-title":"Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells","volume":"183","author":"Carlsten","year":"2009","journal-title":"J Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.4049\/jimmunol.171.12.6891","article-title":"Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma","volume":"171","author":"Doubrovina","year":"2003","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.1073\/pnas.0501953102","article-title":"Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells","volume":"102","author":"Groh","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e31210","DOI":"10.1371\/journal.pone.0031210","article-title":"Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection","volume":"7","author":"Lehner","year":"2012","journal-title":"PLoS ONE"},{"key":"B87","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.smim.2006.03.005","article-title":"NKG2D and cytotoxic effector function in tumor immune surveillance","volume":"18","author":"Hayakawa","year":"2006","journal-title":"Semin Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","article-title":"Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB","volume":"96","author":"Groh","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B89","first-page":"6178","article-title":"Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity","volume":"62","author":"Pende","year":"2002","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ijc.21510","article-title":"Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients","volume":"118","author":"Watson","year":"2006","journal-title":"Int J Cancer"},{"key":"B91","first-page":"8996","article-title":"MICA\/NKG2D-mediated immunogene therapy of experimental gliomas","volume":"63","author":"Friese","year":"2003","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1523-1747.2002.01700.x","article-title":"Expression of stress-induced MHC class I related chain molecules on human melanoma","volume":"118","author":"Vetter","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","article-title":"Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia","volume":"102","author":"Salih","year":"2003","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"B95","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1074-7613(00)80222-8","article-title":"Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice","volume":"12","author":"Cerwenka","year":"2000","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/77793","article-title":"Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages","volume":"1","author":"Diefenbach","year":"2000","journal-title":"Nat Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1126\/science.285.5428.730","article-title":"An activating immunoreceptor complex formed by NKG2D and DAP10","volume":"285","author":"Wu","year":"1999","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35093109","article-title":"Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity","volume":"413","author":"Diefenbach","year":"2001","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.1073\/pnas.201238598","article-title":"Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo","volume":"98","author":"Cerwenka","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","article-title":"NKG2D ligands-critical targets for cancer immune escape and therapy","volume":"9","author":"Schmiedel","year":"2018","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/imr.12600","article-title":"Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells","volume":"280","author":"Raulet","year":"2017","journal-title":"Immunol Rev"},{"key":"B102","doi-asserted-by":"publisher","first-page":"905","DOI":"10.4049\/jimmunol.176.2.905","article-title":"IFN-dependent down-regulation of the NKG2D ligand H60 on tumors","volume":"176","author":"Bui","year":"2006","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1084\/jem.20050994","article-title":"NKG2D function protects the host from tumor initiation","volume":"202","author":"Smyth","year":"2005","journal-title":"J Exp Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"key":"B105","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1172\/JCI69369","article-title":"Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis","volume":"123","author":"Liu","year":"2013","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.4049\/jimmunol.1002092","article-title":"NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease","volume":"185","author":"Hanaoka","year":"2010","journal-title":"J Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e108326","DOI":"10.1371\/journal.pone.0108326","article-title":"Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease","volume":"9","author":"Huergo-Zapico","year":"2014","journal-title":"PLoS ONE"},{"key":"B108","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/CMR.0000000000000126","article-title":"In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15","volume":"25","author":"Vuletic","year":"2015","journal-title":"Melanoma Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Ferrari de Andrade","year":"2018","journal-title":"Science"},{"key":"B110","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2045-3329-2-8","article-title":"Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis","volume":"2","author":"Berghuis","year":"2012","journal-title":"Clin Sarcoma Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"E1677","DOI":"10.3390\/ijms18081677","article-title":"Regulation of NKG2D-dependent NK cell functions: the yin and the yang of receptor endocytosis","volume":"18","author":"Molfetta","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20150792","article-title":"DNAM-1 controls NK cell activation via an ITT-like motif","volume":"212","author":"Zhang","year":"2015","journal-title":"J Exp Med"},{"key":"B113","unstructured":"KeggPathway\n          Natural Killer Cell Mediated Cytotoxicity - Homo Sapiens2019"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival","volume":"5","author":"Genssler","year":"2016","journal-title":"Oncoimmunology."},{"key":"B115","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1582-4934.2011.01343.x","article-title":"NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin","volume":"16","author":"Esser","year":"2012","journal-title":"J Cell Mol Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B118","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/icb.2013.45","article-title":"Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody","volume":"91","author":"Zhang","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"B120","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"B121","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T10:43:35Z","timestamp":1580294615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":122,"alternative-id":["10.3389\/fimmu.2020.00040"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00040","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"article-number":"40"}}